Literature DB >> 1727764

Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint.

F M Klion1, T L Fabry, M Palmer, F Schaffner.   

Abstract

Increasing use of liver transplantation and new treatment regimens necessitate an accurate estimate of prognosis in primary biliary cirrhosis. To test the usefulness of the Mayo model for this purpose, the R value of the model was calculated for a group of 28 patients after each patient encounter and plotted against time. The data were best described by two linear regressions. For the period 10-2 years before death, the average increase in R value was 0.23 annually [R = 7.1-0.23 x time (in years)]. In the last 2 years of life, the average increase in R value was 1.4. This period could be fit by the expression R = 8.2-1.4 x time (in years). The increase in R value represents the natural progression of primary biliary cirrhosis and can be used for evaluating treatment of patients.

Entities:  

Mesh:

Year:  1992        PMID: 1727764     DOI: 10.1016/0016-5085(92)91815-l

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  2 in total

1.  Predictive role of serum procollagen III peptide and Knodell's index in survival prognosis of patients with hepatitis B virus liver cirrhosis.

Authors:  Zarko Babić; Ante Bilić; Dobroslav Babić; Vjekoslav Jagić; Branko Nikolić; Martina Sunić
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

Review 2.  Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.

Authors:  Melissa Palmer; Arie Regev; Keith Lindor; Mark I Avigan; Lara Dimick-Santos; William Treem; John F Marcinak; James H Lewis; Frank A Anania; Daniel Seekins; Benjamin L Shneider; Naga Chalasani
Journal:  Aliment Pharmacol Ther       Date:  2019-11-25       Impact factor: 8.171

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.